<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18495">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02138110</url>
  </required_header>
  <id_info>
    <org_study_id>InVivo-100-101</org_study_id>
    <nct_id>NCT02138110</nct_id>
  </id_info>
  <brief_title>Pilot Study of Clinical Safety of the PLGA Poly-L-Lysine Scaffold for the Treatment of Complete (ASIA A) Traumatic Acute Spinal Cord Injury</brief_title>
  <official_title>Pilot Study of Clinical Safety of the PLGA Poly-L-Lysine Scaffold for the Treatment of Complete (ASIA A) Traumatic Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InVivo Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InVivo Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate whether the Scaffold is safe and feasible for the treatment of complete
           functional spinal cord injury as determined by no degradation in paralysis level or
           sensory motor neurological function beyond that typically seen in the ASIA A subject.

        -  To gather preliminary evidence of clinical effectiveness of the Scaffold, including
           improvement of ASIA Impairment Scale, sensory scores, motor scores, bladder and bowel
           function, neurological tests, and The Spinal Cord Independence Measure III.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of all Adverse Device Effects of any kind/seriousness.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASIA score changes from baseline at 3 months, 6 months, and 12 months post implantation.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Traumatic Acute Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>PLGA Poly-L-Lysine Scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PLGA Poly-L-Lysine Scaffold</intervention_name>
    <arm_group_label>PLGA Poly-L-Lysine Scaffold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 - 55 years

          -  ASIA A traumatic spinal cord injury (T3-T11) confirmed by neurosurgeon, occurring
             within past 10 days

          -  Non-penetrating contusion injury no less than 4 mm diameter and limited to 2
             contiguous vertebral levels

        Exclusion Criteria:

          -  Incomplete spinal cord injury (ASIA B, C, D, E)

          -  Terminally ill

          -  Significant spinal conditions other than lesion to be treated

          -  Spinal cord injury associated with traumatic brain injury

          -  Subject on long term mechanical ventilation

          -  Penetrating injuries

          -  Radiographic evidence of parenchymal disassociation or anatomic transection where the
             contusion completely bridges a full cross-section of the spinal cord
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lou Vaickus, MD</last_name>
    <role>Study Director</role>
    <affiliation>InVivo Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin Neff</last_name>
    <phone>617-863-5581</phone>
    <email>kneff@invivotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Furet, MD</last_name>
      <phone>520-626-8000</phone>
      <email>oscarf@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Ali A Baaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina NeuroSurgery and Spine Associates/Carolinas Rehabilitation</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Boltes</last_name>
      <phone>704-831-4006</phone>
      <email>peggy.boltes@cnsa.com</email>
    </contact>
    <contact_backup>
      <last_name>Marybeth Whitney</last_name>
      <phone>704-355-1409</phone>
      <email>Marybeth.Whitney@carolinashealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Domagoj Coric, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Bockenek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spinal Cord Injury (SCI)</keyword>
  <keyword>Complete (ASIA A) Traumatic Acute Spinal Cord Injury</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
